BURLINGTON, Mass. – September 10, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today the appointment of Andrew J. Suchoff as Chief Human Resources Officer to oversee a workforce of 12,000 people in more than 40 countries around the globe.
Suchoff brings nearly 30 years of experience to the job, including about a decade overseas managing talent in London, Singapore and Geneva. He has built HR infrastructure to support rapid global growth, led integrations of key acquisitions, overseen dramatic cultural transformations and designed learning and development organizations recognized for excellence by Training magazine.
As the global HR leader of a high-growth company with 30,000 employees, Suchoff led large teams of HR professionals and managed global recruiting across multiple legal and regulatory environments in 22 countries.
“Andrew brings inVentiv exactly the experience, global perspective and deep skills we need to build a high-value organization known as a great place to work,” said Paul Meister, CEO of inVentiv Health. “His diverse experience working across multiple industries, including life sciences, gives him immediate insight attracting and retaining top talent.”
Suchoff’s experience includes working as a Managing Partner at TAG Global Systems, EVP of Global Human Resources at Stream Global Services, and Chief Human Resources Officer at Insulet Corporation. As the SVP of U.S. Human Resources for Serono International, acquired by Merck KGaA, he played a key role in shifting the company culture toward greater collaboration and significantly improved organizational capability.
A graduate of Northeastern University, Suchoff will report to CEO Paul Meister and serve on the company’s Executive Leadership team. He replaces Duncan Harwood, who is returning to Texas for personal reasons, but who will continue to provide counsel to inVentiv Health.
About inVentiv Health
Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 12,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.